Adaptimmune Therapeutics PLC (ADAPY) vs NeuroSense Therapeutics Ltd. (NRSN)

Adaptimmune Therapeutics PLC and NeuroSense Therapeutics Ltd. are both Biotechnology companies. Adaptimmune Therapeutics PLC and NeuroSense Therapeutics Ltd. are of similar size ($14.6M and $14.0M). NeuroSense Therapeutics Ltd. has the higher net margin (0.00% vs −262.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, NeuroSense Therapeutics Ltd. leads on 7 and Adaptimmune Therapeutics PLC on 3.

Valuation

Metric ADAPY NRSN Biotechnology median
P/E n/m n/m 7.88
P/S 0.12 n/m 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.12 n/m 10.73
Earnings yield (2,166.67%) (179.97%) (28.84%)
Free cash flow yield (2,380.45%) (339.53%) (23.03%)

Profitability

Metric ADAPY NRSN Biotechnology median
Gross margin 94.81% — 65.16%
Operating margin (427.75%) 0.00% 0.00%
Net margin (262.46%) 0.00% 0.00%
Free cash flow margin (288.20%) 0.00% 0.00%
Return on equity (1,349.52%) 0.00% (57.72%)
Return on assets 0.00% 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY NRSN Biotechnology median
Revenue growth (TTM) (53.99%) — 5.64%
EPS growth (last fiscal year) 142.86% 20.45% —
Revenue growth, 5-year CAGR 8.40% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY NRSN Biotechnology median
Debt to equity (0.36) 0.00 0.00
Current ratio 1.52 0.71 4.73
Net debt to EBITDA 0.47 0.01 0.96

Dividend

Metric ADAPY NRSN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ADAPY NRSN Biotechnology median
Market cap 14.55m 14.04m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack